The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Induces apoptosis in U937 cells at 1µg/ml, within 5 hours. At 0.5-2.0µg/ml, induces apoptosis in various thyroid carcinoma lines within 18 hours. User must determine optimal concentrations and time course for induction. Please note that this protein does not require a cross-linking enhancer to exhibit this potent activity.
< 0.100 Eu/µg
>95% by SDS-PAGE .
Induces apoptosis in responsive cells, especially transformed cells and tumors. Prolonged storage of TRAIL dilutions at a lower ionic strength
than that of the product storage buffer may cause the TRAIL to precipitate. It is therefore recommended that dilution to working concentrations be done shortly before application to cells.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
Tumor necrosis factor ligand superfamily member 10
Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.
Widespread; most predominant in spleen, lung and prostate.
SDS-PAGE analysis of ab157018 (4-20% acrylamide) stained with Coomassie Blue. MWs (kDa) of marker proteins are indicated by numbers to the left. NOTE: TRAIL migrates anomalously in this gel system, with an apparent MW of ~18 kDa.
has not yet been referenced specifically in any publications.
Publishing research using ab157018? Please let us know so that we can cite the reference in this datasheet.
Customer reviews and Q&As
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up